16.05.2017 • NewsElaine BurridgePfizerR&D

Pfizer and Sangamo Link on Hemophilia A

(c) anyaivanova/Shutterstock
(c) anyaivanova/Shutterstock

Major US drugmaker Pfizer is collaborating with Sangamo Therapeutics to develop and commercialize gene therapy programs for the rare blood disorder hemophilia A. The agreement includes SB-525, one of Sangamo’s four lead product candidates.

The US Food and Drug Administration has cleared initiation of human clinical trials for SB-525, which has been granted orphan drug status.

Under the terms of the deal, Sangamo will receive an upfront payment of $70 million from Pfizer as well as potential milestone payments of up to $475 million, including up to $300 million for the development and commercialization of SB-525 and up to $175 million for additional candidate drugs developed under the partnership. The California-based biotech will also receive tiered double-digit royalties on net sales.

Sangamo will conduct the SB-525 Phase I/II clinical study and certain manufacturing activities. For its part, Pfizer will be operationally and financially responsible for research, development, manufacturing and commercialization activities for SB-525 and additional products.

“We believe SB-525 has the potential to be a best-in-class therapy that may provide patients with stable and durable levels of Factor VIII protein with a single administration treatment,” said Mikael Dolsten, president of worldwide research and development at Pfizer.

More than 150,000 people worldwide are believed to have the disorder, which is caused by a genetic mutation that results in insufficient activity of Factor VIII, a blood clotting protein.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.